Sign inJoin waitlistJoin the waitlist

AP

Alan Pestronk

Section Chief, Neuromuscular Diseases · Washington University

Credentials: · · · ·

History

Neuromuscular Clinical Laboratory · Washington University
1989–Present
Neuromuscular Diseases Section · Washington University
Present
Washington University
Present

Washington University School of Medicine
1977–1978
Neuromuscular Medicine
Johns Hopkins University School of Medicine
1976–1977
Pathology-Anatomic and Clinical
Washington University/B-JH/SLCH Consortium
1970–1974
Neurology
Johns Hopkins Hospital
Chief ResidentUntil 1974
1970–1973
Johns Hopkins School of Medicine
1966–1970
Princeton University
1966

Research

Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS
Nature · 2013 · 1,248 citations
Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein
Nature Genetics · 2004 · 1,118 citations
A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside
Case report · Annals of Neurology · 1988 · First of 8 authors · 582 citations

DD
Daniel Drachman
47 papers
GL
Glenn Lopate
32 papers · 1 as a resident
Jerry Mendell
29 papers
Anne Connolly
25 papers
Conrad Weihl
24 papers · 2 as a fellow
Muhammad Al-Lozi
24 papers · 8 as a resident
John Day
19 papers
Matthew Harms
19 papers
Diana Bharucha-Goebel
15 papers
Robert Baloh
15 papers
Craig Zaidman
14 papers · 2 as a fellow
EB
Elena Bravver
14 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $563.2K · Washington University
1997–2007
Aging and the Neuronal Cytoskeleton
National Institute on Aging · R01
Contact PI · $400.2K · Washington University
1988–1992
Antiganglioside Antibodies in Motor Neuron Disorders
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $200.3K · Washington University
1988–1991
General Clinical Research Center
National Center for Research Resources · M01
Project lead · Washington University

Clinical trials

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy
Principal investigator · Completed · Phase 2
Ultragenyx Pharmaceutical Inc
2012–2013